DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Relapsed Refractory Acute Myeloid Leukemia R R Emerging drugs, the Relapsed Refractory Acute Myeloid Leukemia R R pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Relapsed Refractory Acute Myeloid Leukemia R R pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Relapsed Refractory Acute Myeloid Leukemia R R clinical trials studies, Relapsed Refractory Acute Myeloid Leukemia R R NDA approvals (if any), and product development activities comprising the technology, Relapsed Refractory Acute Myeloid Leukemia R R collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline landscape @ Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Outlook Report
Relapsed Refractory Acute Myeloid Leukemia R R Overview
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses.
Recent Developmental Activities in the Relapsed/Refractory Acute Myeloid Leukemia Treatment Landscape
For further information, refer to the detailed Relapsed Refractory Acute Myeloid Leukemia R R Drugs Launch, Relapsed Refractory Acute Myeloid Leukemia R R Developmental Activities, and Relapsed Refractory Acute Myeloid Leukemia R R News, click here for Relapsed Refractory Acute Myeloid Leukemia R R Ongoing Clinical Trial Analysis
Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.
Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Relapsed/refractory acute myeloid leukemia (AML). The companies which have their Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage, i.e. Phase I/II include, Ascentage Pharma.
Find out more about the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Segmentation, Therapeutics Assessment, and Relapsed Refractory Acute Myeloid Leukemia R R Emerging Drugs @ Relapsed Refractory Acute Myeloid Leukemia R R Treatment Landscape
Scope of the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report
Dive deep into rich insights for drugs for Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Companies and Therapies, click here @ Relapsed Refractory Acute Myeloid Leukemia R R Unmet Needs and Analyst Views
Introduction
Got Queries? Find out the related information on Relapsed Refractory Acute Myeloid Leukemia R R Mergers and acquisitions, Relapsed Refractory Acute Myeloid Leukemia R R Licensing Activities @ Relapsed Refractory Acute Myeloid Leukemia R R Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/